Pharmaceutical Law

Home ServicesPharmaceutical Law

Pharmaceutical Law

Diwan Advocates

Pharmaceutical Law Practice

Every pill that reaches a patient in India has passed through one of the world's most complex regulatory journeys. A molecule discovered in a laboratory must survive clinical trials, satisfy the Central Drugs Standard Control Organisation, navigate price controls, survive patent challenges, clear customs, and find its way through a distribution chain that stretches across hundreds of thousands of pharmacies. That is before it faces competition from generic manufacturers, scrutiny from SEBI if the company is listed, and the possibility of a product liability claim if something goes wrong.

India is not a minor player in this story. It is the pharmacy of the world. The country supplies over sixty percent of global vaccine demand, accounts for twenty percent of global generic exports by volume, and is home to more US FDA-approved manufacturing facilities outside the United States than any other country. The legal framework that governs this industry touches every aspect of a pharmaceutical company's existence, from the moment a drug is discovered to the moment it is discontinued.

At Diwan Advocates, we have built a pharmaceutical law practice that understands both the industry and the law. We advise manufacturers, importers, distributors, contract research organisations, hospital groups, and international pharmaceutical companies on the full range of legal issues that arise across the drug lifecycle. Our work covers regulatory compliance, licensing, intellectual property, price control disputes, clinical trial governance, product liability, and criminal enforcement under the Drugs and Cosmetics Act.

The legal issues in this sector never arise in isolation. A dispute over a drug patent under the Patents Act, 1970 will be shaped by the regulatory data generated during the approval process under the New Drugs and Clinical Trials Rules, 2019. A price control challenge under the Drugs Prices Control Order, 2013 will depend on data that the company has reported to CDSCO and NPPA. A criminal prosecution under the Drugs and Cosmetics Act can trigger securities disclosure obligations if the company is listed on a stock exchange. We connect these threads so that our clients are protected across all of them.

Drug Regulatory Approvals and Licensing

Getting a drug to market in India requires a series of regulatory approvals that must be obtained in the right sequence and maintained through ongoing compliance. A misstep at any stage can delay a product launch by years or result in the cancellation of a licence that has taken considerable time and investment to obtain.

New Drug Approvals and CDSCO

The Central Drugs Standard Control Organisation (CDSCO) is the national regulatory authority responsible for approval of new drugs, clinical trial authorisations, and import licences. The approval pathway for a new drug or new molecular entity is governed by the New Drugs and Clinical Trials Rules, 2019 which introduced a more structured framework for submission, expert committee review, and approval timelines. We assist applicants in preparing dossiers, responding to CDSCO queries, and representing clients before the Subject Expert Committees and the Drug Controller General of India.

India introduced an accelerated approval pathway for drugs that have already received regulatory approval in reference jurisdictions such as the US, EU, UK, Japan, and Australia. Navigating this pathway requires a precise understanding of which data requirements can be waived and what post-approval commitments the applicant must make. We advise originator and generic companies on this pathway and handle the legal aspects of expedited submissions.

Manufacturing Licences and GMP Compliance

Every pharmaceutical manufacturer in India must hold a valid manufacturing licence issued by the State Licensing Authority under Schedule M of the Drugs and Cosmetics Rules, 1945. Schedule M prescribes the Good Manufacturing Practice standards that facilities must comply with, and has been substantially revised to align with WHO-GMP guidelines. Licence suspension, cancellation, and regulatory action by drug inspectors are governed by Sections 22 to 33 of the Drugs and Cosmetics Act, 1940. We advise manufacturers on maintaining GMP compliance, represent them during inspections, and defend licence suspension and cancellation proceedings before licensing authorities and in writ proceedings before High Courts.

Cross-Law Note: Pharmaceutical manufacturing facilities that supply to the US market are also subject to inspection by the US Food and Drug Administration. An FDA import alert or warning letter issued to an Indian facility triggers immediate questions about disclosure obligations under SEBI's LODR Regulations if the company is listed, and may affect the validity of technology transfer agreements or export contracts. We coordinate advice across the regulatory, securities, and contractual dimensions of such situations.

Import and Export Licences

Importing drugs and active pharmaceutical ingredients into India requires a separate import licence from CDSCO. Exports of pharmaceuticals are governed by the Foreign Trade (Development and Regulation) Act, 1992 and the Export and Import Policy, as well as destination country regulatory requirements. We advise importers and exporters on licence applications, restricted and prohibited items, documentation requirements, and customs classification disputes that arise at Indian ports and border checkpoints.

Cross-Law Note: Import of drugs for personal use or for clinical research purposes is regulated differently from commercial import. Pharmaceutical companies sponsoring clinical trials in India must ensure that investigational products imported for trial use comply with both CDSCO requirements and the customs classification applicable to investigational medicinal products, which is frequently a source of practical difficulty at the import stage.

Clinical Trials and Research Governance

India is one of the most significant destinations globally for clinical research, offering a large and genetically diverse patient population, cost efficiencies, and a framework of qualified investigators and research institutions. The legal framework governing clinical trials is set out in the New Drugs and Clinical Trials Rules, 2019, which introduced significant reforms following the controversy over clinical trial deaths and compensation disputes in the earlier part of this decade.

Trial Authorisation and Ethics Committee Oversight

A clinical trial can only begin after CDSCO issues a trial authorisation and an independent Ethics Committee registered with CDSCO approves the trial protocol. We advise sponsors, contract research organisations, and investigator sites on preparing CDSCO submissions, responding to queries during the review process, and structuring the contractual framework between sponsors, CROs, and sites in a way that is consistent with the regulatory requirements and manages liability appropriately.

Informed Consent and Participant Rights

Informed consent requirements under the 2019 Rules are detailed and specific. Audio-visual recording of the consent process is mandatory for certain categories of trial. Compensation for trial-related injury or death must be offered and calculated according to a prescribed formula. We advise on the documentation requirements for valid informed consent, the liability of sponsors and investigators when consent is alleged to be defective, and the compensation framework for trial-related adverse events.

Cross-Law Note: Clinical trial participants who suffer injury or death have remedies under the Consumer Protection Act, 2019 in addition to the compensation formula under the NDCT Rules. The interaction between regulatory compensation and civil liability has not been fully settled by Indian courts, and sponsors need to understand their exposure under both frameworks before a trial begins.

Bioequivalence Studies and Generic Drug Approval

Generic drugs approved in India must demonstrate bioequivalence to the reference listed drug through studies conducted at CDSCO-approved bioequivalence study centres. The standards for study design, statistical analysis, and data integrity have been tightened significantly in recent years following instances of data manipulation at certain facilities. We advise generic manufacturers on the regulatory requirements for BE studies, represent them in disputes with CDSCO over study acceptability, and handle the legal aspects of partnerships with approved BE centres.

Pharmaceutical Patents and Intellectual Property

India's patent framework for pharmaceuticals is shaped by Section 3(d) of the Patents Act, 1970, one of the most distinctive and debated provisions in global pharmaceutical patent law. Section 3(d) prevents the grant of patents for new forms of known substances unless they demonstrate significantly enhanced efficacy. This provision has been central to India's position as a supplier of affordable generics and has been extensively litigated, including the landmark Supreme Court judgment in Novartis AG v. Union of India (2013).

Patent Prosecution and Portfolio Strategy

We assist pharmaceutical companies in prosecuting patent applications before the Indian Patent Office, advising on claim drafting strategies that navigate Section 3(d), responding to examination reports and objections, and building patent portfolios that protect the full range of a company's innovations including compounds, formulations, dosage forms, manufacturing processes, and delivery systems.

Patent Oppositions and Invalidity Challenges

The Patents Act provides for pre-grant opposition by any person and post-grant opposition by an interested person. Generic manufacturers frequently file pre-grant oppositions against originator drug patents on the ground that the invention does not satisfy the Section 3(d) threshold or lacks novelty and inventive step. We represent both originators defending their patents and generic companies challenging them, before the Patent Office, the Intellectual Property Appellate Board's successor jurisdiction, and in High Court proceedings.

Compulsory Licensing

Section 84 of the Patents Act allows any person to apply for a compulsory licence three years after the grant of a patent if the patented invention is not available to the public at reasonably affordable prices, or is not worked in India to an adequate extent. India's only compulsory licence to date was granted by the Patent Office in Natco Pharma v. Bayer (2012) for the anti-cancer drug sorafenib. We advise companies seeking compulsory licences and those defending against such applications on the legal standards applicable and the strategic considerations involved.

Cross-Law Note: Pharmaceutical patents and regulatory data are connected but separate forms of protection. While the Patents Act governs patent rights, India does not yet have a formal data exclusivity regime of the kind that exists in the US and EU under which regulatory data submitted for drug approval is protected from reliance by generic competitors for a defined period. This gap is a live policy debate, and its eventual resolution will significantly affect the balance between originator and generic interests in the Indian market.

Drug Price Control and NPPA Proceedings

The Drugs Prices Control Order, 2013 issued under the Essential Commodities Act, 1955 is administered by the National Pharmaceutical Pricing Authority (NPPA). The DPCO fixes ceiling prices for scheduled formulations, which are those listed in the National List of Essential Medicines, and monitors the prices of non-scheduled drugs to prevent extraordinary price increases.

Ceiling Price Compliance and Audit

Pharmaceutical companies that manufacture or sell scheduled formulations must ensure that their prices do not exceed the ceiling prices notified by NPPA. The pricing calculations involve the market-based methodology prescribed by the DPCO and require careful tracking of price filings, depot price changes, and the handling of pack size variations. We advise companies on DPCO compliance programmes, review price filings for legal risk, and represent companies in proceedings before NPPA for price revisions, exemptions, or corrections to ceiling price calculations.

Overpricing Demands and Recovery Proceedings

When NPPA determines that a company has sold a drug above the applicable ceiling price, it issues a demand for the overcharged amount plus interest. These demands can cover multiple years of sales and reach substantial amounts. A company that fails to deposit the demand within the prescribed period faces the possibility of criminal prosecution under the Essential Commodities Act. We represent companies challenging NPPA demand notices before the High Courts on grounds including incorrect ceiling price computation, wrong identification of the applicable schedule entry, and errors in the period of overcharging alleged.

Cross-Law Note: Drug price control proceedings can intersect with competition law in complex ways. The CCI has examined whether NPPA's price fixation methodology itself raises competition concerns, and has also investigated whether pharmaceutical companies have engaged in anti-competitive conduct by using ancillary products such as medical devices or consumables to circumvent price controls on drugs. Our competition and pharmaceutical law teams work together on matters at this intersection.

Trade Margins and Distribution Chain Pricing

The DPCO framework regulates not just manufacturer prices but also the margins available to stockists and retailers. Trade margin capping, which has been applied to non-scheduled drugs through government orders, is a particularly active area where the legal basis and implementation methodology have been challenged by trade associations and manufacturers. We advise on the legal framework for trade margin orders and represent clients before the NPPA and in writ proceedings.

Medical Devices Regulation

Medical devices were brought under the Drugs and Cosmetics Act framework and are now primarily governed by the Medical Device Rules, 2017. The scope of the MDR has been progressively expanded, and all medical devices are now required to be registered with CDSCO under a phased timeline. Class A and B devices follow a simplified registration pathway, while Class C and D devices require full pre-market approval including clinical data.

We advise medical device manufacturers and importers on device classification, registration requirements, quality management system compliance, and clinical investigation regulations. The boundaries between drugs, medical devices, and combination products are often unclear, and the classification of a product can have significant regulatory and commercial consequences. We advise on product classification disputes and represent clients challenging incorrect classification decisions before CDSCO.

Cross-Law Note: Medical devices that are also subject to price control, such as coronary stents and knee implants which have been brought under DPCO price ceilings, face a dual compliance burden under both the MDR and the DPCO. Companies in this segment need advice that covers both the regulatory and pricing dimensions of their product.

Product Liability and Adverse Drug Events

A defective drug or medical device can cause serious harm. When it does, the manufacturer, importer, and distributor face potential liability under the Consumer Protection Act, 2019, civil suits for negligence and product liability, and in serious cases, criminal prosecution under the Drugs and Cosmetics Act, 1940. The Consumer Protection Act, 2019 introduced a product liability chapter that imposes strict liability on manufacturers for defective products and on service providers for deficient services, which includes hospitals and pharmacies.

Drug Recalls and Market Withdrawals

When a quality defect or safety signal is identified in a marketed drug, the company must act quickly to assess the scope of the problem, notify CDSCO, and initiate a voluntary recall if required. Mishandling a recall situation, whether by delay, incomplete execution, or inadequate communication, significantly increases both regulatory and legal exposure. We advise companies on recall procedures, CDSCO notification obligations, communication with the trade and with patients, and the documentation required to demonstrate that the recall was conducted competently.

Pharmacovigilance and Safety Reporting

Pharmaceutical companies are required to maintain pharmacovigilance systems and report adverse drug reactions to the Indian Pharmacopoeia Commission's Pharmacovigilance Programme of India and to CDSCO. Failures in safety reporting are a common ground for regulatory action. We advise companies on structuring their pharmacovigilance obligations, conducting internal audits of safety reporting systems, and responding to CDSCO queries about adverse event reporting gaps.

Cross-Law Note: Adverse drug reaction data held by a pharmaceutical company may be sought in evidence in civil litigation by patients or their families. Companies need to understand the legal status of pharmacovigilance data, the extent to which it is protected from disclosure in litigation, and the consequences of inadequate signal detection and reporting for their civil liability exposure.

Enforcement, Inspections, and Criminal Prosecution

The Drugs and Cosmetics Act, 1940 creates offences for the manufacture, sale, or distribution of adulterated drugs, spurious drugs, misbranded drugs, and drugs that do not comply with prescribed standards. Penalties range from fines to imprisonment of up to life in cases involving adulterated drugs that cause death or grievous hurt. Drug inspectors have wide powers of inspection, sampling, and seizure, and state drug controllers and CDSCO can initiate prosecution.

We represent pharmaceutical companies, directors, and responsible persons facing drug inspector actions, show-cause notices, licence suspension proceedings, and criminal prosecutions under the D&C Act. Defending a prosecution under this Act requires a combination of scientific knowledge about drug quality standards, procedural expertise in criminal defence, and an understanding of the licensing framework within which the company operates. Our team brings all three together.

Directors and officers of pharmaceutical companies can face personal criminal liability if they were in charge of the company's affairs at the time the offence was committed. We advise on the conditions under which personal liability arises, the defences available to individuals who were not directly involved in the default, and the steps that companies should take to ensure that compliance frameworks reduce the risk of personal criminal exposure.

Cross-Law Note: A criminal prosecution under the Drugs and Cosmetics Act against a listed pharmaceutical company will trigger disclosure obligations under SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, which require prompt disclosure of material litigation. Companies need a coordinated response that addresses both the criminal proceedings and the securities law disclosure simultaneously.

Competition Law in the Pharmaceutical Sector

The Competition Commission of India has paid particular attention to the pharmaceutical sector in recent years. Issues that have attracted CCI scrutiny include excessive pricing of patented drugs, refusal by originators to license patents to generic manufacturers, exclusive dealing arrangements between pharmaceutical companies and distributors, and alleged cartel behaviour in the supply of hospital medicines. We advise pharmaceutical companies on competition compliance and represent them in CCI investigations under the Competition Act, 2002.

The interface between patent law and competition law is particularly live in the pharmaceutical sector. An originator that uses patent enforcement to block generic entry may face not only a challenge under the Patents Act but also an allegation of abuse of dominant position under the Competition Act. We advise on navigating both frameworks and on the extent to which legitimate patent enforcement can be distinguished from anti-competitive conduct.

See Also: Diwan Advocates' Taxation Law Practice document covers the income tax and GST implications of pharmaceutical transactions, including tax treatment of R&D expenditure, transfer pricing in pharma group companies, and customs duty classification for APIs and finished formulations.

Why Diwan Advocates for Pharmaceutical Law?

Pharma-Specific Expertise	We understand the science behind the law. Our team advises on drug development, regulatory submissions, manufacturing standards, and clinical trial compliance with a depth that generalist firms rarely offer.
Regulatory and Litigation Combined	From CDSCO submissions to High Court writ petitions against arbitrary licensing decisions, we handle the full spectrum without needing to refer clients elsewhere.
IP and Regulatory Integration	Patent strategy, data exclusivity, and regulatory approval are deeply interconnected in pharma. We coordinate across both areas so that commercial interests are protected from development through to market.
Cross-Border Advisory	India's pharmaceutical industry is heavily export-oriented. We advise on FDA compliance, WHO-GMP certifications, FTA implications, and international licensing agreements alongside domestic regulatory work.
Crisis Response	Drug recalls, enforcement actions, product liability claims, and regulatory investigations require immediate and coordinated action. We are available when those situations arise.

Legislative Reference Index

The following table consolidates the principal statutes and regulatory frameworks that govern India's pharmaceutical sector, with notes on their relevance to legal practice in this industry.

Legislation	Relevance in Pharmaceutical Matters	Reference
Drugs and Cosmetics Act, 1940	The foundational statute governing manufacture, distribution, sale, and import of drugs and cosmetics in India. Licences, standards, and enforcement all flow from this Act.	View ->
Drugs and Cosmetics Rules, 1945	The operational rules under the D&C Act. Covers GMP standards, Schedule H and H1 drugs, labelling, clinical trials, and new drug approvals.	View ->
New Drugs and Clinical Trials Rules, 2019	Governs clinical trials, bioequivalence studies, and approval of new drugs and medical devices. Introduced accelerated approval pathways and ethics committee oversight.	View ->
Patents Act, 1970	Section 3(d) restricts evergreening of pharmaceutical patents. The Act governs product and process patent protection, compulsory licensing, and patent linkage debates.	View ->
Drugs (Prices Control) Order, 2013 (DPCO)	Issued under the Essential Commodities Act. NPPA administers price ceilings on scheduled formulations. Overpricing allegations carry civil and criminal consequences.	View ->
Essential Commodities Act, 1955	Provides the parent power for pharmaceutical price control. DPCO and drug stock regulations are issued under this Act.	View ->
Medical Device Rules, 2017	Regulates manufacture, import, sale, and clinical investigation of medical devices, in vitro diagnostics, and combination products under the D&C Act framework.	View ->
Competition Act, 2002	Pharmaceutical markets are susceptible to anti-competitive conduct. The CCI has investigated excessive pricing, refusal to license, and cartel behaviour in drug markets.	View ->
Consumer Protection Act, 2019	Defective drugs and cosmetics attract product liability under the Consumer Protection Act. Consumers can file complaints before District, State, and National Commissions.	View ->
Foreign Exchange Management Act, 1999	Governs royalty payments, technology transfer fees, and FDI in the pharmaceutical sector. International licensing and collaboration agreements must comply with FEMA and RBI guidelines.	View ->

India's pharmaceutical industry carries the weight of global health access on its shoulders.

The legal framework that governs it is complex, consequential, and constantly evolving.

Diwan Advocates is here to help clients navigate it with confidence.

Diwan Advocates | Delhi, India

Dr. Farrukh Khan

Dr. Farrukh Khan is the founding partner of the firm, and is also the administrative head. He is placed amongst the most eloquent and skilful lawyers in the country with above par legal knowledge....